Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy

Jia‐Feng Wu, Chee‐Seng Lee, Wen‐Hsi Lin, Yung‐Ming Jeng, Huey‐Ling Chen, Yen‐Hsuan Ni, Hong‐Yuan Hsu, Mei‐Hwei Chang – 27 February 2018 – We investigated the utility of transient elastography (TE) for diagnosing biliary atresia (BA) in cholestatic infants and predicting the outcome of BA. Forty‐eight cholestatic infants (9‐87 days of age) with direct bilirubin level >1 mg/dL were enrolled. Liver stiffness measurement (LSM) by TE was performed during the cholestasis workup, and 15 subjects were diagnosed as BA.

Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolism

Preeti Pathak, Cen Xie, Robert G. Nichols, Jessica M. Ferrell, Shannon Boehme, Kristopher W. Krausz, Andrew D. Patterson, Frank J. Gonzalez, John Y.L. Chiang – 27 February 2018 – Bile acids activate farnesoid X receptor (FXR) and G protein–coupled bile acid receptor‐1 (aka Takeda G protein–coupled receptor‐5 [TGR5]) to regulate bile acid metabolism and glucose and insulin sensitivity. FXR and TGR5 are coexpressed in the enteroendocrine L cells, but their roles in integrated regulation of metabolism are not completely understood.

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort

Paul Kwo, Michael W. Fried, K. Rajender Reddy, Consuelo Soldevila‐Pico, Saro Khemichian, Jama Darling, Phillippe J. Zamor, Andrew A. Napoli, Beatrice Anduze‐Faris, Robert S. Brown – 27 February 2018 – We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child‐Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced fibrosis/cirrhosis.

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis

Hannah C. Jeffery, Manjit K. Braitch, Chris Bagnall, James Hodson, Louisa E. Jeffery, Rebecca E. Wawman, Lin Lee Wong, Jane Birtwistle, Helen Bartlett, Ansgar W. Lohse, Gideon M. Hirschfield, Jessica Dyson, David Jones, Stefan G. Hubscher, Paul Klenerman, David H. Adams, Ye H. Oo – 26 February 2018 – Autoimmune hepatitis (AIH) is an immune‐mediated liver disease currently treated by immunosuppressive medications with significant side effects. Thus, novel mechanistic treatments are greatly needed.

Subscribe to